The role of SLCO1B1 genotyping in lowering cardiovascular risk

References

• 1. Roden DM, McLeod HL, Relling MV et al. Pharmacogenomics. Lancet 394(10197), 521–532 (2019).
  Medline CASGoogle Scholar
• 2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 526(7573), 343–350 (2015).
  Medline CASGoogle Scholar
• 3. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  Medline CASGoogle Scholar
• 4. Armitage J, Baigent C, Barnes E et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 393(10170), 407–415 (2019).
  MedlineGoogle Scholar
• 5. Iyengar SS, Puri R, Narasingan SN et al. Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1. J. Assoc. Physicians India 64(Suppl. 3), 7–52 (2016).
  Medline CASGoogle Scholar
• 6. Joint committee for guideline revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J. Geriatr. Cardiol. 15(1), 1–29 (2018).
  MedlineGoogle Scholar
• 7. Force UPST. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 316(19), 1997–2007 (2016).
  MedlineGoogle Scholar
• 8. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(25), e1082–e1143 (2019).
  MedlineGoogle Scholar
• 9. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020).
  MedlineGoogle Scholar
• 10. Newman CB, Preiss D, Tobert Jonathan A et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 39(2), e38–e81(2019).
  Medline CASGoogle Scholar
• 11. Zhang H, Plutzky J, Skentzos S et al. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 158(7), 526–534 (2013).
  MedlineGoogle Scholar
• 12. Navar AM, Peterson ED, Li S et al. Prevalence and management of symptoms associated with statin therapy in community practice: insights From the PALM (Patient and Provider Assessment of Lipid Management) registry. Circ Cardiovasc Qual Outcomes. 11(3), e004249 (2018).
  MedlineGoogle Scholar
• 13. Cholesterol Treatment Trialists C, Baigent C, Blackwell L et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
  MedlineGoogle Scholar
• 14. Alfirevic A, Neely D, Armitage J et al. Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther. 96(4), 470–476 (2014).
  Medline CASGoogle Scholar
• 15. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J. Clin. Med. 9(1), 22 (2019).
  Google Scholar
• 16. Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J. Clin. Lipidol. 10(4), 739–747 (2016).
  MedlineGoogle Scholar
• 17. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059), 2532–2561 (2016).
  Medline CASGoogle Scholar
• 18. Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann. Intern. Med. 167(4), 221–227 (2017).
  MedlineGoogle Scholar
• 19. Salami JA, Warraich H, Valero-Elizondo J et al. National trends in statin use and expenditures in the US adult population From 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2(1), 56–65 (2017).
  MedlineGoogle Scholar
• 20. Colantonio LD, Rosenson RS, Deng L et al. Adherence to statin therapy among US adults between 2007 and 2014. J. Am. Heart Assoc. 8(1), e010376 (2019).
  MedlineGoogle Scholar
• 21. Sigglekow F, Horsburgh S, Parkin L. Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users. PLoS ONE 15(11), e0242424 (2020).
  Medline CASGoogle Scholar
• 22. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J. Clin. Lipidol. 7(5), 472–483 (2013).
  MedlineGoogle Scholar
• 23. Bradley CK, Wang TY, Li S et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J. Am. Heart Assoc. 8(7), e011765 (2019).
  MedlineGoogle Scholar
• 24. Hovingh GK, Gandra SR, McKendrick J et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis 245, 111–117 (2016).
  Medline CASGoogle Scholar
• 25. Rosenson RS, Gandra SR, McKendrick J et al. Identification and management of statin-associated symptoms in clinical practice: extension of a clinician survey to 12 further countries. Cardiovasc. Drugs Ther. 31(2), 187–195 (2017).
  MedlineGoogle Scholar
• 26. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: insights from the understanding statin use in America and gaps in patient education survey. J. Clin. Lipidol. 12(1), 78–88(2018).
  MedlineGoogle Scholar
• 27. Soran H, France M, Adam S, Iqbal Z, Ho JH, Durrington PN. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis 306, 33–40 (2020).
  Medline CASGoogle Scholar
• 28. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2), 177–186 (2007).
  Medline CASGoogle Scholar
• 29. Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J. Clin. Lipidol. 11(1), 70–79.e71 (2017).
  MedlineGoogle Scholar
• 30. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 4(3), 206–213 (2019).
  MedlineGoogle Scholar
• 31. Khalaf K, Johnell K, Austin PC et al. Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54,872 patients. Eur. Heart J. Cardiovasc. Pharmacother. 7(2), 141–147 (2021).
  MedlineGoogle Scholar
• 32. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med. Decis. Making 35(1), 114–131 (2015).
  MedlineGoogle Scholar
• 33. Butalia S, Lee-Krueger RCW, McBrien KA et al. Barriers and facilitators to using statins: a qualitative study with patients and family physicians. CJC Open 2(6), 530–538 (2020).
  MedlineGoogle Scholar
• 34. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
  MedlineGoogle Scholar
• 35. Kee PS, Chin PKL, Kennedy MA, Maggo SDS. Pharmacogenetics of statin-induced myotoxicity. Front. Genet. 11, 575678 (2020).
  Medline CASGoogle Scholar
• 36. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9(1), 19–33 (2008).
  CASGoogle Scholar
• 37. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 96(4), 423–428 (2014).
  Medline CASGoogle Scholar
• 38. de Keyser CE, Peters BJ, Becker ML et al. The SLCO1B1 c.521T >C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet. Genomics 24(1), 43–51 (2014).
  Medline CASGoogle Scholar
• 39. Carr DF, Francis B, Jorgensen AL et al. Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research Datalink. Clin. Pharmacol. Ther. 106(6), 1353–1361 (2019).
  Medline CASGoogle Scholar
• 40. Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 94(37), e1268 (2015).
  Medline CASGoogle Scholar
• 41. Xiang Q, Zhang XD, Mu GY et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur. J. Clin. Pharmacol. 77(4), 569–581 (2021).
  Medline CASGoogle Scholar
• 42. Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. doi: 10.1038/s41397-021-00208-w (2021) (Epub ahead of print).
  MedlineGoogle Scholar
• 43. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 92(4), 414–417 (2012).
  Medline CASGoogle Scholar
• 44. Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc. Res. 114(8), 1073–1081 (2018).
  Medline CASGoogle Scholar
• 45. Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front. Pharmacol. 11, 595219 (2020).
  Medline CASGoogle Scholar
• 46. The Dutch Pharmacogenetics Working Group. Pharmacogenetics recommendations. (2021). https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica/pharmacogenetics-1/pharmacogenetics
  Google Scholar
• 47. Lamoureux F, Duflot T. French Network of P. Pharmacogenetics in cardiovascular diseases: state of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie 72(2), 257–267 (2017).
  MedlineGoogle Scholar
• 48. Picard N, Boyer JC, Etienne-Grimaldi MC et al. Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie 72(2), 185–192 (2017).
  MedlineGoogle Scholar
• 49. Dunnenberger HM, Crews KR, Hoffman JM et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55, 89–106 (2015).
  Medline CASGoogle Scholar
• 50. Cavallari LH, Beitelshees AL, Blake KV et al. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin. Transl. Sci. 10(3), 143–146 (2017).
  Medline CASGoogle Scholar
• 51. Weitzel KW, Cavallari LH, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. Pharm. Res. 34(8), 1551–1555 (2017).
  Medline CASGoogle Scholar
• 52. Volpi S, Bult CJ, Chisholm RL et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin. Pharmacol. Ther. 103(5), 778–786(2018).
  MedlineGoogle Scholar
• 53. Freimuth RR, Formea CM, Hoffman JM, Matey E, Peterson JF, Boyce RD. Implementing genomic clinical decision support for drug-based precision medicine. CPT Pharmacometrics Syst. Pharmacol. 6(3), 153–155 (2017).
  Medline CASGoogle Scholar
• 54. Njie GJ, Proia KK, Thota AB et al. Clinical decision support systems and prevention: a community guide cardiovascular disease systematic review. Am. J. Prev. Med. 49(5), 784–795 (2015).
  MedlineGoogle Scholar
• 55. Hopkins DP. Community Preventive Services Task F. Clinical decision support systems recommended to prevent cardiovascular disease. Am. J. Prev. Med. 49(5), 796–799 (2015).
  MedlineGoogle Scholar
• 56. O'Donnell PH, Wadhwa N, Danahey K et al. Pharmacogenomics-based point-of-care clinical decision support significantly alters drug prescribing. Clin. Pharmacol. Ther. 102(5), 859–869 (2017).
  MedlineGoogle Scholar
• 57. Sebastian A, Carroll JC, Oldfield LE et al. Effect of genetics clinical decision support tools on health-care providers' decision making: a mixed-methods systematic review. Genet. Med. 23(4), 593–602 (2021).
  MedlineGoogle Scholar
• 58. Liu M, Vnencak-Jones CL, Roland BP et al. A tutorial for pharmacogenomics implementation through end-to-end clinical decision support based on ten years of experience from PREDICT. Clin. Pharmacol. Ther. 109(1), 101–115 (2021).
  MedlineGoogle Scholar
• 59. van der Wouden CH, Bank PCD, Ozokcu K, Swen JJ, Guchelaar HJ. Pharmacist-initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes (Basel) 10(6), 416 (2019).
  Google Scholar
• 60. Herr TM, Peterson JF, Rasmussen LV, Caraballo PJ, Peissig PL, Starren JB. Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network. J. Am. Med. Inform. Assoc. 26(2), 143–148 (2019).
  MedlineGoogle Scholar
• 61. Formea CM, Nicholson WT, Vitek CR. An inter-professional approach to personalized medicine education: one institution's experience. Per Med. 12(2), 129–138 (2015).
  CASGoogle Scholar
• 62. Rigter T, Jansen ME, de Groot JM, Janssen SWJ, Rodenburg W, Cornel MC. Implementation of pharmacogenetics in primary care: a multi-stakeholder perspective. Front. Genet. 11, 10 (2020).
  MedlineGoogle Scholar
• 63. Lanting P, Drenth E, Boven L et al. Practical barriers and facilitators experienced by patients, pharmacists and physicians to the implementation of pharmacogenomic screening in Dutch outpatient hospital care-an explorative pilot study. J. Pers. Med. 10(4), 293 (2020).
  MedlineGoogle Scholar
• 64. Olson JE, Rohrer Vitek CR, Bell EJ et al. Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). Genet. Med. 19(7), 819–825 (2017).
  Medline CASGoogle Scholar
• 65. Christian C, Borden BA, Danahey K et al. Pharmacogenomic-based decision support to predict adherence to medications. Clin. Pharmacol. Ther. 108(2), 368–376 (2020).
  Medline CASGoogle Scholar
• 66. Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC. Impact of SLCO1B1 pharmacogenetic testing on patient and healthcare outcomes: a systematic review. Clin. Pharmacol. Ther. 106(2), 360–373 (2018).
  MedlineGoogle Scholar
• 67. Li JH, Joy SV, Haga SB et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J. Pers. Med. 4(2), 147–162 (2014).
  MedlineGoogle Scholar
• 68. Peyser B, Perry EP, Singh K et al. Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings. Circ. Genom. Precis. Med. 11(9), e002228 (2018).
  Medline CASGoogle Scholar
• 69. Vassy JL, Gaziano JM, Green RC et al. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol: a randomized clinical trial. JAMA Network Open 3(12), e2027092–e2027092 (2020).
  MedlineGoogle Scholar
• 70. Shi Y, Graves JA, Garbett SP et al. A decision-theoretic approach to panel-based, preemptive genotyping. MDM Policy Pract. 4(2), (2019).
  MedlineGoogle Scholar
• 71. Zhu Y, Moriarty JP, Swanson KM et al. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet. Med. 23(3), 461–470 (2020).
  MedlineGoogle Scholar
• 72. Dong OM, Wheeler SB, Cruden G et al. Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health 23(1), 61–73 (2020).
  MedlineGoogle Scholar